Image_3_Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation.jpeg

ObjectiveRecently, circulating donor-derive cell free DNA (dd-cfDNA) has gained growing attention in the field of solid organ transplantation. The aim of the study was to analyze circulating dd-cfDNA levels in graft rejection, ACR and AMR separately for each rejection type compared with non-rejection, and assessed the diagnostic potential of dd-cfDNA levels in predicting graft rejection after lung transplantation.MethodsA systematic search for relevant articles was conducted on Medline, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases without restriction of languages. The search date ended on June 1, 2023. STATA software was used to analyze the difference between graft rejection, ACR, AMR and stable controls, and evaluate the diagnostic performance of circulating dd-cfDNA in detecting graft rejection.ResultsThe results indicated that circulating dd-cfDNA levels in graft rejection, ACR, and AMR were significantly higher than non-rejection (graft rejection: SMD=1.78, 95% CI: 1.31-2.25, I2 = 88.6%, P2 = 89.0%, P 2 = 89.8%, P ConclusionCirculating dd-cfDNA could be used as a non-invasive biomarker to distinguish the patients with graft rejection from normal stable controls.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023440467.</p

Image_2_Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation.jpeg

ObjectiveRecently, circulating donor-derive cell free DNA (dd-cfDNA) has gained growing attention in the field of solid organ transplantation. The aim of the study was to analyze circulating dd-cfDNA levels in graft rejection, ACR and AMR separately for each rejection type compared with non-rejection, and assessed the diagnostic potential of dd-cfDNA levels in predicting graft rejection after lung transplantation.MethodsA systematic search for relevant articles was conducted on Medline, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases without restriction of languages. The search date ended on June 1, 2023. STATA software was used to analyze the difference between graft rejection, ACR, AMR and stable controls, and evaluate the diagnostic performance of circulating dd-cfDNA in detecting graft rejection.ResultsThe results indicated that circulating dd-cfDNA levels in graft rejection, ACR, and AMR were significantly higher than non-rejection (graft rejection: SMD=1.78, 95% CI: 1.31-2.25, I2 = 88.6%, P2 = 89.0%, P 2 = 89.8%, P ConclusionCirculating dd-cfDNA could be used as a non-invasive biomarker to distinguish the patients with graft rejection from normal stable controls.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023440467.</p

Image_1_Circulating donor-derived cell-free DNA as a marker for rejection after lung transplantation.jpeg

ObjectiveRecently, circulating donor-derive cell free DNA (dd-cfDNA) has gained growing attention in the field of solid organ transplantation. The aim of the study was to analyze circulating dd-cfDNA levels in graft rejection, ACR and AMR separately for each rejection type compared with non-rejection, and assessed the diagnostic potential of dd-cfDNA levels in predicting graft rejection after lung transplantation.MethodsA systematic search for relevant articles was conducted on Medline, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases without restriction of languages. The search date ended on June 1, 2023. STATA software was used to analyze the difference between graft rejection, ACR, AMR and stable controls, and evaluate the diagnostic performance of circulating dd-cfDNA in detecting graft rejection.ResultsThe results indicated that circulating dd-cfDNA levels in graft rejection, ACR, and AMR were significantly higher than non-rejection (graft rejection: SMD=1.78, 95% CI: 1.31-2.25, I2 = 88.6%, P2 = 89.0%, P 2 = 89.8%, P ConclusionCirculating dd-cfDNA could be used as a non-invasive biomarker to distinguish the patients with graft rejection from normal stable controls.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023440467.</p

Serum levels of VEGF-C in ovarian cancer patients in relation to clinic-pathological variables of tumor.

<p>Serum levels of VEGF-C in ovarian cancer patients in relation to clinic-pathological variables of tumor.</p

Clinical characteristics of KIRC patients.

<p>Clinical characteristics of KIRC patients.</p

Kaplan-Meier survival curves. Percent survival rate was stratified by VEGF-C level.

<p>Kaplan-Meier survival curves. Percent survival rate was stratified by VEGF-C level.</p

Differentially expressed miRNAs between KIRC tissues and normal tissues.

<p>Differentially expressed miRNAs between KIRC tissues and normal tissues.</p

A three-microRNA signature as a diagnostic and prognostic marker in clear cell renal cancer: An <i>In Silico</i> analysis

<div><p>Accumulating evidence has demonstrated that some specific miRNAs were aberrantly expressed in renal clear cell carcinoma and participated in many biological processes. The aim of this study was to investigate a panel of miRNA signature for diagnosis and prognosis of renal clear cell carcinoma (KIRC). Here, we performed a comprehensive analysis for miRNA expression profiles and corresponding clinical information of 516 KIRC patients from The Cancer Genome Atlas (TCGA). In the study, a total of 63 differentially expressed miRNAs were identified, of which 34 were up-regulated and 29 were down-regulated. We constructed a panel of three-miRNA that were significantly associated with KIRC diagnosis and KIRC patients' prognosis. The three-miRNA signature reached a sensitivity of 98.3% and a specificity of 97.2% in the diagnosis of KIRC. Using the three-miRNA signature, we classified the KIRC patients into high-risk group and low-risk group. The Kaplan- Meier curves showed that KIRC patients with high risk scores had significantly worsen overall survival (OS) and disease free survival (DFS) than KIRC patients with low risk scores. In the univariate and multivariate Cox regression analysis, three-miRNA signature was an independent prognostic factor in OS. In conclusion, the three-miRNA signature could be used as a diagnostic and prognostic biomarker in KIRC, and therefore, may help to provide significant clinical implication for the treatment of KIRC.</p></div

Kaplan-Meier survival curves for 15 miRNAs associated with overall survival.

<p>Kaplan-Meier survival curves for 15 miRNAs associated with overall survival.</p

Serum levels of VEGF-C in ovarian cancer and non-cancer groups.

<p>Serum levels of VEGF-C in ovarian cancer and non-cancer groups.</p